Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Alpendurada, Francisco ^a   Smith, Gill C ^a,b   Carpenter, John Paul ^a,b   Nair, Sunil V ^c   Tanner, Mark A ^a   Banya, Winston ^a   Dessi, Carlo ^d   Galanello, Renzo ^d   Walker, John Malcolm ^c   Pennell, Dudley J ^a,b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d Osp Regionale per le Microcitemie   (Italy)

Author keywords

deferiprone; deferoxamine; right ventricular function; thalassaemia major

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; PLACEBO; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; SIDEROPHORE;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEART HEMOSIDEROSIS; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; THALASSEMIA MAJOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALYSIS OF VARIANCE; BETA THALASSEMIA; CHI SQUARE DISTRIBUTION; CONVALESCENCE; DOPPLER ECHOCARDIOGRAPHY; DRUG COMBINATION; DRUG EFFECT; HEART STROKE VOLUME; HEMOSIDEROSIS; HOSPITALIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; THERAPY; TIME;

ADULT; ANALYSIS OF VARIANCE; BETA-THALASSEMIA; CHI-SQUARE DISTRIBUTION; DEFEROXAMINE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEMOSIDEROSIS; HUMANS; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MALE; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIDEROPHORES; STROKE VOLUME; THERAPEUTICS; TIME FACTORS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84860555772     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-8     Document Type: Article

References (36)

1. Survival and causes of death in thalassaemia major. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S, Lancet 1989 8653 27 30 (Pubitemid 19158169)
2. Survival in medically treated patients with homozygous beta-thalassemia. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR, N Engl J Med 1994 331 574 8 10.1056/NEJM199409013310903 8047081 (Pubitemid 24265699)
3. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A, Haematologica 2004 89 1187 193 15477202 (Pubitemid 39390442)
4. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassemia. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ, Lancet 2002 360 516 20 10.1016/S0140-6736(02)09740-4 12241655 (Pubitemid 35232104)
5. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Modell B, Khan M, Darlison M, Lancet 2000 355 2051 2 10.1016/S0140-6736(00)02357-6 10885361 (Pubitemid 30339248)
6. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R, Blood 2006 107 3738 44 10.1182/blood-2005-07-2948 16352815
7. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassaemia major: a retrospective analysis. Piga A, Caglioti C, Fogliacco E, Tricta F, Haematologica 2003 88 489 96 12745268 (Pubitemid 36648438)
8. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A, Blood 2006 107 3733 7 10.1182/blood-2005-07-2933 16373663
9. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Kolnagou A, Kontoghiorghes GJ, Hemoglobin 2006 30 239 49 10.1080/ 03630260600642567 16798649 (Pubitemid 43977326)
10. Combined therapy with deferiprone and desferrioxamine. Wonke B, Wright C, Hoffbrand AV, Br J Haematol 1998 103 361 4 10.1046/j.1365-2141.1998.01002.x 9827905 (Pubitemid 28522439)
11. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ, Circulation 2007 115 1876 84 10.1161/CIRCULATIONAHA.106. 648790 17372174 (Pubitemid 46598901)
12. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ, J Cardiovasc Magn Reson 2008 10 12 10.1186/1532-429X-10-12 18298856
13. Right ventricular cardiomyopathy in beta-thalassaemia major. Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC, Eur Heart J 2002 23 147 56 10.1053/euhj.2001.2709 11785997 (Pubitemid 35204233)
14. Relation of Myocardial T2* to Right Ventricular Function in Thalassaemia Major. Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, Porter JB, Banya W, He T, Smith GC, Pennell DJ, Eur Heart J 2010 31 1648 54 10.1093/eurheartj/ehq106 20413399
15. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Maceira AM, Prasad SK, Khan M, Pennell DJ, Eur Heart J 2006 27 2879 88 10.1093/eurheartj/ehl336 17088316 (Pubitemid 44871471)
16. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ, Eur Heart J 2001 22 2171 9 10.1053/euhj.2001.2822 11913479 (Pubitemid 33139463)
17. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ, J Magn Reson Imaging 2003 18 33 9 10.1002/jmri.10332 12815637 (Pubitemid 36791266)
18. Myocardial T2* measurements in iron-overloaded thalassemia: An in vivo study to investigate optimal methods of quantification. He T, Gatehouse PD, Smith GC, Mohiaddin RH, Pennell DJ, Firmin DN, Magn Reson Med 2008 60 1082 9 10.1002/mrm.21744 18956471
19. Statistical methods for assessing agreement between two methods of clinical measurement. Bland JM, Altman DG, Lancet 1986 1 307 10 2868172 (Pubitemid 16134762)
20. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ, Am Heart J 2004 147 218 23 10.1016/j.ahj.2003. 10.005 14760316 (Pubitemid 38176819)
21. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S, J Cardiovasc Magn Reson 2005 7 5 775 82 10.1080/10976640500295516 16353438 (Pubitemid 41770055)
22. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. Carpenter JP, Alpendurada F, Deac M, Maceira A, Garbowski M, Kirk P, Walker JM, Porter JB, Shah F, Banya W, He T, Smith GC, Pennell DJ, J Cardiovasc Magn Reson 2010 12 24 10.1186/1532-429X-12-24 20416084
23. On T2* magnetic resonance and cardiac iron. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ, Circulation 2011 123 1519 28 10.1161/CIRCULATIONAHA.110.007641 21444881
24. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Juilliere Y, Barbier G, Feldmann L, Grentzinger A, Danchin N, Cherrier F, Eur Heart J 1997 18 276 80 9043845 (Pubitemid 27107590)
25. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. Di Salvo TG, Mathier M, Semigran MJ, Dec GW, J Am Coll Cardiol 1995 25 1143 53 10.1016/0735-1097(94)00511-N 7897128
26. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L, J Am Coll Cardiol 2001 37 183 8 10.1016/S0735-1097(00) 01102-5 11153735 (Pubitemid 32051736)
27. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. Larose E, Ganz P, Reynolds HG, Dorbala S, Di Carli MF, Brown KA, Kwong RY, J Am Coll Cardiol 2007 49 855 62 10.1016/j.jacc.2006.10.056 17320743
28. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry GJ, White M, Aban IB, Mujib M, Dell'Italia LJ, Ahmed A, Circulation 2010 121 252 8 10.1161/CIRCULATIONAHA.109.887570 20048206
29. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW, N Engl J Med 1994 331 567 73 10.1056/NEJM199409013310902 8047080 (Pubitemid 24265698)
30. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C, Blood 2003 101 4172 9 10.1182/blood-2002-08-2382 12511418 (Pubitemid 36857901)
31. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dess C, Leoni G, Muroni PP, Galanello R, Haematologica 2005 90 1309 14 16219566 (Pubitemid 41503645)
32. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V, Br J Haematol 2010 148 466 75 10.1111/j.1365-2141.2009.07970.x 19912219
33. Cardiopulmonary interactions in healthy children and children after simple cardiac surgery: the effects of positive and negative pressure ventilation. Shekerdemian LS, Bush A, Lincoln C, Shore DF, Petros AJ, Redington AN, Heart 1997 78 587 93 9470877 (Pubitemid 28034210)
34. Pulmonary hypertension in patients with thalassemia major. Derchi G, Fonti A, Forni GL, Galliera EO, Cappellini MD, Turati F, Policlinico OM, Am Heart J 1999 138 384 10426856 (Pubitemid 29379695)
35. Cardiac status in well-treated patients with thalassemia major. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M, Eur J Haematol 2004 73 359 66 10.1111/j.1600-0609.2004.00304.x 15458515 (Pubitemid 39349917)
36. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction. La Vecchia L, Zanolla L, Varotto L, Bonanno C, Spadaro GL, Ometto R, Fontanelli A, Am Heart J 2001 142 181 9 10.1067/mhj.2001.116071 11431676 (Pubitemid 32595392)